Skip to main content
. Author manuscript; available in PMC: 2020 Feb 11.
Published in final edited form as: Cancer Cell. 2019 Jan 24;35(2):267–282.e7. doi: 10.1016/j.ccell.2018.12.010

Figure 8: PDAC outcomes and molecular features.

Figure 8:

(A-D) Overall (left) and progression free (right) survival in unpaired primaries stratified by TP53 bi-allelic inactivation (A), CDKN2A bi-allelic inactivation (B), hypoxia score (C), or Moffitt expression-based subtyping (D). (E and F) Responses to neoadjuvant chemotherapy, reported as either partial response or stable disease, stratified by hypoxia score (E) or expression-based subtypes (F). See also Tables S4 and S5.